Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

Summary

This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.

Timeline

Start

2013-01

Primary completion

2014-03

Completion

2014-03

Outcome

Outcome not reported

Stopped (Enrollment): “Portfolio prioritization due to slow enrollment and variable spectrum of potential complement abnormalities in DDD patients.”

Drugs

Indications